Lightpoint Medical has developed a novel imaging device to improve success in cancer surgery by helping surgeons to remove cancerous tissue, while leaving healthy tissue intact.
The groundbreaking device brings real-time molecular imaging to the operating room, improving health outcomes for cancer patients. The technology is based on the use of Cerenkov luminescence imaging. Dr David Tuch, CEO and Founder, recognised this would have significant diagnostic potential when combined with imaging techniques that observe metabolic processes.
As an intraoperative device, it can be used to guide surgeons so that they can avoid leaving behind microscopic cancerous cells, increasing the likelihood that all target tissue is removed in one surgery. This would prevent patients needing repeat surgeries and minimise any delays to follow-on treatments.
The device can also reduce healthcare costs by making both surgery and follow-on treatment more efficient.
Support from the SME Leaders Programme has allowed David to strengthen skills in strategic marketing and competitive strategy through bespoke training. Since receiving the award in 2017, David’s team has doubled in size to 22 employees. Lightpoint Medical has also raised approximately £4 million in grant funding from organisations in the UK and US and successfully closed a £5 million Series B fundraising round in 2018.
Lightpoint Medical is now working on clinical validation and early commercialisation of its first robotic probe for cancer surgery.
Associated Programme
